Dyne Therapeutics, Inc. Common Stock (DYN) Stock Price
DYNStock
$14.25−13.22%52W
Market Cap$2.66B
P/E—
PEG Ratio—
Div yield—
Beta1.26
DYN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-37.97%
Price vs S&P 500 (4W)-15.44%
VGM Score39.92
DYN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.75 | -$1.08 | -44.28%(-$0.33) | |
| Q1 2026 | -$0.78 | -$0.73 | +6.65%(+$0.05) | |
| Q4 2025 | -$0.76 | -$0.73 | +4.41%(+$0.03) | |
| Q3 2025 | -$0.85 | -$0.76 | +10.08%(+$0.09) | |
| Q2 2025 | -$0.93 | -$0.97 | -3.92%(-$0.04) |
DYN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.20
4.19
4.24
4.24
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
DYNDyne Therapeutics, Inc. Common Stock | — | — | D | — | — | — | — | $14.25 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Dyne Therapeutics, Inc. Common Stock
Dyne Therapeutics is a clinical-stage biopharmaceutical company developing treatments for genetically driven neuromuscular diseases. Its proprietary FORCE platform addresses a critical delivery challenge to muscle tissue and the central nervous system that limits existing therapies. The company has multiple programs in clinical development targeting distinct neuromuscular indications.